Ginkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity business

Reuters02-27

<a href="https://laohu8.com/S/DNA">Ginkgo Bioworks</a> posts fall in Q4 revenue; co to divest biosecurity business

Overview

Biotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improving
Company to divest biosecurity business, focusing on autonomous labs
Company plans to invest in autonomous labs, expanding Boston facility

Outlook

Ginkgo expects total cash burn of $(150)-$(125) million in 2026
Company focuses on autonomous labs as core platform for biotechnology research
Ginkgo plans to complete biosecurity business divestiture in first half of 2026

Result Drivers

CELL ENGINEERING DECLINE - Q4 Cell Engineering revenue decreased 26% due to ongoing program rationalization as part of restructuring activities

Company press release: ID:nPn4RtdMka

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$81 mln

Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 4.1% below its February 25 closing price of $9.38

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614079008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614079008","market":"us","top_or_hot":-1,"title":"Ginkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity business","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> posts fall in Q4 revenue; co to divest biosecurity business</title></head><body><p><span>Overview</span></p><ul><li><p>Biotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improving</p></li><li><p>Company to divest biosecurity business, focusing on autonomous labs</p></li><li><p>Company plans to invest in autonomous labs, expanding Boston facility</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ginkgo expects total cash burn of $(150)-$(125) million in 2026</p></li><li><p>Company focuses on autonomous labs as core platform for biotechnology research</p></li><li><p>Ginkgo plans to complete biosecurity business divestiture in first half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CELL ENGINEERING DECLINE - Q4 Cell Engineering revenue decreased 26% due to ongoing program rationalization as part of restructuring activities</p></li></ul><p>Company press release: <span>ID:nPn4RtdMka</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"sell\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", no \"hold\" and 3 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Holdings Inc is $9.00, about 4.1% below its February 25 closing price of $9.38</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> posts fall in Q4 revenue; co to divest biosecurity business</title></head><body><p><span>Overview</span></p><ul><li><p>Biotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improving</p></li><li><p>Company to divest biosecurity business, focusing on autonomous labs</p></li><li><p>Company plans to invest in autonomous labs, expanding Boston facility</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ginkgo expects total cash burn of $(150)-$(125) million in 2026</p></li><li><p>Company focuses on autonomous labs as core platform for biotechnology research</p></li><li><p>Ginkgo plans to complete biosecurity business divestiture in first half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CELL ENGINEERING DECLINE - Q4 Cell Engineering revenue decreased 26% due to ongoing program rationalization as part of restructuring activities</p></li></ul><p>Company press release: <span>ID:nPn4RtdMka</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"sell\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", no \"hold\" and 3 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Holdings Inc is $9.00, about 4.1% below its February 25 closing price of $9.38</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM1KO:1","article_id":"2614079008","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614079008","pubTimestamp":1772141769,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks posts fall in Q4 revenue; co to divestbiosecurity businessOverviewBiotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improvingCompany to divest biosecurity business, f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc.","BK4109":"特种化学制品","BK4121":"生命科学工具和服务","BK4139":"生物科技"},"translate_title":"Ginkgo Bioworks公布第四季度收入下降；公司将剥离生物安全业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":0.9},"content_text":"Ginkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity businessOverviewBiotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improvingCompany to divest biosecurity business, focusing on autonomous labsCompany plans to invest in autonomous labs, expanding Boston facilityOutlookGinkgo expects total cash burn of $(150)-$(125) million in 2026Company focuses on autonomous labs as core platform for biotechnology researchGinkgo plans to complete biosecurity business divestiture in first half of 2026Result DriversCELL ENGINEERING DECLINE - Q4 Cell Engineering revenue decreased 26% due to ongoing program rationalization as part of restructuring activitiesCompany press release: ID:nPn4RtdMkaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Net Income-$81 mlnAnalyst CoverageThe current average analyst rating on the shares is \"sell\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", no \"hold\" and 3 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 4.1% below its February 25 closing price of $9.38For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614079008","isCrawlerRequest":true}